Source: Virtual Congress 2020 – Scientific advances in airway pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Desch (Biberach, Germany), R. Sennewald (Biberach, Germany), A. Eleftheraki (Biberach, Germany), H. Kögler (Ingelheim am Rhein, Germany), C. Diefenbach (Biberach, Germany). Safety, pharmacokinetics and pharmacodynamics of BI 1323495 in healthy males. 3296

Member's Comments

No comment yet.

Related content which might interest you: Multiple-dose study of AMG 853 in healthy adults: Safety and pharmacokinetics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Source: International Congress 2017 – COPD management Year: 2017 Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Multiple-dose study of AMG 317 in adults with asthma: pharmacokinetics and safety Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Safety and tolerability of single doses of AZD5069 in healthy volunteers Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Single-dose, first-in-human study of AMG 317: safety and pharmacokinetics in healthy and asthmatic adults Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004 The effect of fluconazole on the pharmacokinetics of ensifentrine in healthy individuals Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021 Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006 Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Pharmacokinetics (PK) and pharmacodynamics (PD) of tetomilast in stable COPD subjects Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006 Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011